Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients
| Autor: | Flavio Vincenti, Amado Andrés, Norio Yoshimura, José Manuel González-Posada, Gabriel Choukroun, Edward H. Cole, Lionel Rostaing, Mysore S. Anil Kumar, Kazuhide Saito, Björn Nashan, Silvio Nadalin, Richard Moore, Thomas Becker |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Nephrology
Graft Rejection medicine.medical_specialty Basiliximab medicine.medical_treatment Biopsy Calcineurin Inhibitors Pharmacology Models Biological Placebos Daclizumab Internal medicine medicine Animals Humans Antilymphocyte Serum Immunosuppression Therapy Transplantation Thymoglobulin business.industry Interleukin-2 Receptor alpha Subunit Immunosuppression Receptors Interleukin-2 Kidney Transplantation Calcineurin Tolerability Immunology Interleukin-2 Rabbits business Immunosuppressive Agents medicine.drug |
| Zdroj: | Transplant international : official journal of the European Society for Organ Transplantation. 19(6) |
| ISSN: | 0934-0874 |
| Popis: | Summary Addition of interleukin-2 receptor antagonist (IL-2RA) induction to calcineurin inhibitor (CNI)-based regimens reduces biopsy-proven acute rejection by 30–40%. IL-2RA induction facilitates early withdrawal of steroids, and supports the safe use of reduced-exposure CNI or delayed CNI introduction. IL-2RAs and rabbit antithymocyte globulin (Thymoglobulin®) show comparable efficacy in patients at standard or low immunologic risk, but the adverse event profiles of lymphocyte-depleting agents are less favorable. IL-2RAs, uniquely, provide effective immunosuppression with similar tolerability to placebo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text